Previous studies of gastric or esophageal cancers report a low frequency of 0-1%.30,31 A higher frequency of BRAF alterations may be observed here due to differences in clinical status compared to other studies (newly diagnosed vs. not responding to therapy) and/or heterogeneity in GEA which has been well documented. This evidence concerns the gene BRAF and esophageal cancer.